Partially loaded antibodies and methods of their conjugation

Details Partially loaded antibodies and methods of their conjugation Partially loaded antibodies and methods of their conjugation

2005-03-02

2010-11-23

Huynh, Phuong (Department: 1644)

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

Attached to antibody or antibody fragment or immunoglobulin;...

C424S001530, C424S178100, C530S391100, C530S391500, C530S391700, C530S405000, C530S408000, C530S412000, C530S413000

Reexamination Certificate

active

07837980

ABSTRACT:
A protein containing one or more activatable groups, e.g., an antibody, is subjected to partial or complete reduction of one or more such bonds to form reactive groups; the resulting protein is reacted with a drug which is reactive with some of the reactive groups, such as certain radiometals, chelating agents, and toxins, so as to form a conjugate useful in, e.g., in vitro diagnosis, in vivo imaging, and therapy.

REFERENCES:
patent: 6884869 (2005-04-01), Senter et al.
patent: 2004/0018194 (2004-01-01), Francisco et al.
patent: 2005/0152894 (2005-07-01), Krummen et al.
patent: 2005/0175619 (2005-08-01), Duffy et al.
patent: 2005/0238649 (2005-10-01), Doronina et al.
patent: 2006/0074008 (2006-04-01), Senter et al.
patent: 2006/0120959 (2006-06-01), De Haen et al.
patent: 2006/0210526 (2006-09-01), Brocchini et al.
patent: WO 2006/034488 (2006-03-01), None
patent: WO 2006/065533 (2006-06-01), None
patent: WO 2006/065533 (2006-06-01), None
Doronina et al, Nature Biotechnology 21(7): 778-941, Jul. 2003.
Sears et al, Proc Nat Acad USA 72(1): 353-357, Jan. 1975.
Del Rosario, R. et al., “Sulfhydryl Site-Specific Cross-Linking and Labeling of Monoclonal Antibodies by a Fluorescent Equlibrium Transfer Alkylation Cross-Link Reagent,”Bioconjugate Chem., 1990, 1, pp. 51-59.
Junutula, J. R. et al., “Rapid identification of reactive cyseteine residues for site-specific labeling of antibody-Fabs”,Journal of Immunological Method, 2008, 332, pp. 41-52.
Wilbur D. et al., “Monoclonal Antibody Fab' Fragment Cross-Linking Using Equlibrium Transfer Alkylation Reagents. A Strategy for Site-Specific Conjugation of Diagnostic and Therapeutic Agents with F (ab')2Fragments,”Bioconjugate Chem., 1994, 5, pp. 220-235.
Doral et al., “Role of Inter-Heavy and Light Chain Disulfide Bonds in the Effector Functions of Human Immunoglobulin IgG1,”Molecular Immunology, 29(12):1487-1491 (1992).
Francisco et al., “cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity,”Blood, 102(4):1458-1465 (Aug. 15, 2003).
Gillies et al., “Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities,”Hum. Antibod. Hybridomas, 1(1):47-54 (1990).
Hamann et al., “Gemtuzumab Ozogamicin, A Potent and Selective Anti-CD33 Antibody—Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia,”Bioconjugate Chem., 13:47-58 (2002).
Lyons et al., “Site-specific attachment to recombinant antibodies via introduced surface cysteine residues,”Prot. Eng., 3(8):703-708 (1990).
Oi et al., “Chimeric Antibodies,”BioTechniques, 4(3):214-221 (1986).
Product description of Mylotarg® (gemtuzumab ozogamicin for Injection), by Wyeth Pharmaceuticals, Inc., Jul. 2004 revision, pp. 1-19.
Qu et al., “Carbohydrates engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates,”J. Immunological Methods, 213:131-144 (1998).
Rodwell et al., “Site-specific covalent modification of monoclonal antibodies: In vitro and in vivo evaluations,”PNAS, 83:2632-2636 (Apr. 1986).
Saito et al., “Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities,”Advanced Drug Delivery Reviews, 55:199-215 (2003).
Stimmel et al., “Site-specific Conjugation on Serine—> Cysteine Variant Monoclonal Antibodies,”J. Biol. Chem., 275(39):30445-30450 (2000).
Sun et al., “Reduction-Alkylation Strategies for the Modification of Specific Monoclonal Antibody Disulfides,”Bioconjugate Chem., 16:1282-1290 (2005).
Written Opinion of Aug. 17, 2006 for International Application PCT/US05/07239.

Affiliated with

Also associated with

Rating

Partially loaded antibodies and methods of their conjugation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Partially loaded antibodies and methods of their conjugation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Partially loaded antibodies and methods of their conjugation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4151361